Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Smith & Nephew Temporarily Halts Sale of Wound Therapy Product in the U.S. - Medical Product Outsourcing
Regulatory

Smith & Nephew Temporarily Halts Sale of Wound Therapy Product in the U.S.

Company must obtain new regulatory clearance, according to FDA.

Smith & Nephew has temporarily ceased commercial distribution of the Renasys negative pressure wound therapy (NPWT) product line in the United States.

This action follows instruction from the U.S. Food and Drug Administration (FDA) to obtain new regulatory clearances through the premarket notification 510(k) process “in respect of certain design enhancements made to Renasys systems,” according to the company.  The applications for clearance have been filed and are awaiting action, officials said.

This action only affects Renasys products in the United States. Other NPWT products, including PICO, Smith & Nephew’s portable, canister-free system, are not affected.

“Smith & Nephew is working cooperatively with the FDA to address the agency’s concerns in order to resume distribution of the products in the United States as soon as possible and regrets any disruption caused to customers,” company officials said in a statement.

Sales of Renasys products in the United States accounted for less than 5 percent of the firm’s global Advanced Wound Management revenue in 2013.

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters